North America Oral Anti-Diabetic Drug Market Size and Share
| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Historical Data Period | 2019 - 2023 |
| Market Size (2025) | USD 19.64 Billion |
| Market Size (2030) | USD 24.71 Billion |
| CAGR (2025 - 2030) | 4.70% |
Major Players *Disclaimer: Major Players sorted in no particular order |
North America Oral Anti-Diabetic Drug Market Analysis by Mordor Intelligence
The North America Oral Anti-Diabetic Drug Market size is estimated at USD 19.64 billion in 2025, and is expected to reach USD 24.71 billion by 2030, at a CAGR of 4.7% during the forecast period (2025-2030).
The North American oral anti-diabetic drug market is anticipated to record significant growth due to the increasing prevalence of diabetes and the rising preference for oral medications. Given the myriad health issues associated with diabetes, patients must maintain their blood glucose levels throughout the day.
The region's escalating diabetes prevalence underscores the growing demand for oral anti-diabetic drugs. For instance, CDC data from November 2023 revealed that the United States alone had about 38.4 million diabetes patients, with an additional 97.6 million adults aged 18 or older classified as prediabetic. The statistics highlighted the region's pressing need for oral anti-diabetic medications, setting the stage for significant market expansion.
A notable shift toward oral medications for diabetes treatment is reshaping the market landscape. A study from PLOS ONE in July 2023 highlighted Mexico's consistent trend of favoring drug-based treatments for type 2 diabetes mellitus. Aligning clinical practices with current guidelines not only steers clear of inappropriate prescriptions but also enhances medical care, potentially leading to better glycemic control for these patients.
The North American oral anti-diabetic drug market is poised for substantial growth, driven by the high diabetics prevalence and the growing adoption of oral medications. As healthcare practices continue to evolve, the demand for effective diabetes management solutions will likely sustain this upward trajectory.
North America Oral Anti-Diabetic Drug Market Trends and Insights
The Biguanide Segment Occupied a Significant Market Share in 2023
The biguanide segment was expected to witness significant growth in 2023 owing to increased regulatory approvals and financial ease for increasing the accessibility of affordable drugs.
Metformin, a biguanide, is primarily used to manage type 2 diabetes. It is also prescribed off-label for conditions like insulin resistance. Since its introduction, metformin has successfully treated a significant number of patients. Endorsed as a first-line prescription by IDF, it boasts a commendable risk/benefit profile.
Given its track record, metformin is the most prescribed oral anti-diabetic globally, accounting for 45-50% of all prescriptions and benefiting over 150 million individuals annually. Its dominance is attributed to a combination of factors, including a well-established safety profile, robust clinical efficacy, high patient adherence, affordability, and widespread availability.
Regulatory endorsements play a pivotal role in bolstering market growth. For instance, in June 2023, the US FDA greenlit Jardiance (empagliflozin) and Synjardy (empagliflozin with metformin) for children aged 10 and above with type 2 diabetes, marking a significant stride in pediatric diabetes treatment.
Similarly, in February 2024, Canada's Health Minister announced the government's progress toward a universal pharmacare program. This initiative, once agreed upon with the provinces, will ensure that Canadians, especially diabetic people, have access to primary diabetes treatments, notably metformin, at an annual cost of around CAD 100 (USD 73). Other common medications for type 2 diabetes, like sulfonylureas and SGLT-2 inhibitors, can range from CAD 100 (USD 73) to over CAD 1,000 (USD 733.5) annually. By enhancing affordability, the initiative aims to not only improve the health of people with diabetes but also stimulate market growth.
The biguanide segment, led by metformin, dominates the North American oral anti-diabetic drugs market. The combination of clinical efficacy, affordability, and strong regulatory support ensures its sustained prominence and growth in the market.
The United States is Expected to Hold a Significant Market Share
The United States commands a significant share of the North American oral anti-diabetic drug market, bolstered by the robust presence of key market players and strong regulatory backing.
Pharmaceutical firms are increasingly focusing on developing drugs that treat diabetes and address associated issues like chronic weight management. For instance, in June 2023, Lilly announced its exploration of orforglipron, the company's inaugural nonpeptide oral GLP-1 receptor agonist. This drug was being studied for type 2 diabetes in the ACHIEVE phase 3 clinical program and chronic weight management in the ATTAIN phase 3 clinical program. A phase 2 trial was also used to compare orforglipron's efficacy in treating type 2 diabetes to placebo and dulaglutide.
Similarly, in November 2023, a US regulatory body approved a novel use for the widely prescribed diabetes medication Mounjaro, endorsing it as a weight-reducing drug.
The United States is poised to maintain its market share, driven by continuous innovation and regulatory support. The ongoing development of drugs that address both diabetes and related conditions like chronic weight management underscores the dynamic nature of this market.
Competitive Landscape
The North American oral anti-diabetes drug market is semi-consolidated, with a few major manufacturers, such as Eli Lilly and Company, AstraZeneca, Sanofi, and Janssen Pharmaceuticals, having a global market presence. In contrast, the remaining manufacturers are confined to other local or regional markets. Companies are focusing on innovations in drugs for diabetes.
North America Oral Anti-Diabetic Drug Industry Leaders
Sanofi
Novo Nordisk A/S
AstraZeneca
Pfizer Inc.
Novartis AG
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- June 2023: The US FDA approved Jardiance (empagliflozin) for treating type 2 diabetes in children aged 10 and above. This approval was hinged on the findings from the DINAMO phase III trial. The trial showcased that Jardiance led to a significant reduction in A1c levels after 26 weeks, compared to a placebo, in participants aged 10-17 with type 2 diabetes.
- January 2023: TheracosBio announced the FDA's approval of Brenzavvy (bexagliflozin), an oral SGLT2 inhibitor. Brenzavvy is specifically meant to complement diet and exercise, aiding in better glycemic control for adults with type 2 diabetes.
North America Oral Anti-Diabetic Drug Market Report Scope
Antihyperglycemic medications are taken orally to lower blood glucose levels. They are frequently employed in the management of type 2 diabetes.
The North American oral anti-diabetic drug market is segmented by drugs, patient type, and geography. By drug, the market is segmented by biguanides, alpha-glucosidase inhibitors, dopamine-d2 receptor agonists, sodium-glucose cotransport-2 (SGLT-2) inhibitor, dipeptidyl peptidase-4 (DPP-4) inhibitors, sulfonylureas, and meglitinides. By patient type, the market is segmented into adults, geriatric, and pediatric. By geography, the market is segmented into the United States, Canada, and Mexico. The report offers the value (USD) for all the above segments.
| Biguanides | |
| Alpha-Glucosidase Inhibitors | |
| Dopamine D2 Receptor Agonist | |
| SGLT-2 Inhibitors | Invokana (Canagliflozin) |
| Jardiance (Empagliflozin) | |
| Farxiga/Forxiga (Dapagliflozin) | |
| Suglat (Ipragliflozin) | |
| DPP-4 Inhibitors | Onglyza (Saxagliptin) |
| Tradjenta (Linagliptin) | |
| Vipidia/Nesina (Alogliptin) | |
| Galvus (Vildagliptin) | |
| Sulfonylureas | |
| Meglitinides |
| Adults |
| Geriatric |
| Pediatric |
| United States |
| Canada |
| Mexico |
| By Drug Types | Biguanides | |
| Alpha-Glucosidase Inhibitors | ||
| Dopamine D2 Receptor Agonist | ||
| SGLT-2 Inhibitors | Invokana (Canagliflozin) | |
| Jardiance (Empagliflozin) | ||
| Farxiga/Forxiga (Dapagliflozin) | ||
| Suglat (Ipragliflozin) | ||
| DPP-4 Inhibitors | Onglyza (Saxagliptin) | |
| Tradjenta (Linagliptin) | ||
| Vipidia/Nesina (Alogliptin) | ||
| Galvus (Vildagliptin) | ||
| Sulfonylureas | ||
| Meglitinides | ||
| By Patient Type | Adults | |
| Geriatric | ||
| Pediatric | ||
| Geography | United States | |
| Canada | ||
| Mexico | ||
Key Questions Answered in the Report
How big is the North America Oral Anti-Diabetic Drug Market?
The North America Oral Anti-Diabetic Drug Market size is expected to reach USD 19.64 billion in 2025 and grow at a CAGR of 4.70% to reach USD 24.71 billion by 2030.
What is the current North America Oral Anti-Diabetic Drug Market size?
In 2025, the North America Oral Anti-Diabetic Drug Market size is expected to reach USD 19.64 billion.
Who are the key players in North America Oral Anti-Diabetic Drug Market?
Sanofi, Novo Nordisk A/S, AstraZeneca, Pfizer Inc. and Novartis AG are the major companies operating in the North America Oral Anti-Diabetic Drug Market.
What years does this North America Oral Anti-Diabetic Drug Market cover, and what was the market size in 2024?
In 2024, the North America Oral Anti-Diabetic Drug Market size was estimated at USD 18.72 billion. The report covers the North America Oral Anti-Diabetic Drug Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the North America Oral Anti-Diabetic Drug Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Page last updated on:
North America Oral Anti-Diabetic Drug Market Report
Statistics for the 2025 North America Oral Anti-Diabetic Drug market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. North America Oral Anti-Diabetic Drug analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
